PhRMA

PhRMA. The Pharmaceutical Research and Manufacturers of America is a prominent trade association and lobbying group representing the country's leading pharmaceutical research and biotechnology companies. Founded in 1958, it is headquartered in Washington, D.C. and is a major voice in debates over healthcare policy, drug pricing, and intellectual property rights. The organization advocates for policies that foster medical innovation and access to medicines, while frequently engaging with entities like the U.S. Congress, the Food and Drug Administration, and the Centers for Medicare & Medicaid Services.

History

The organization was established in 1958, evolving from earlier industry groups during a period of significant growth for the American pharmaceutical industry. Its formation coincided with major advancements in drug discovery, including the development of new vaccines and antibiotics. Over the decades, it has been centrally involved in legislative debates, such as the passage of the Prescription Drug User Fee Act and the Medicare Prescription Drug, Improvement, and Modernization Act. Key historical moments include its advocacy during the HIV/AIDS crisis and its role in shaping the Biologics Price Competition and Innovation Act as part of the Affordable Care Act.

Organization and membership

The association is led by a board of directors comprising executives from member companies, with day-to-day operations managed by President and CEO Stephen J. Ubl. Membership is restricted to pharmaceutical and biotechnology companies that engage in significant research and development of prescription drugs. Notable member firms include Pfizer, Merck & Co., Johnson & Johnson, Eli Lilly and Company, and Amgen. The organization maintains a substantial staff of policy experts, lawyers, and communications professionals, operating primarily from its headquarters in the United States Capitol region to influence federal policy.

Policy positions and advocacy

Its primary advocacy focuses on protecting intellectual property rights, including patent terms and data exclusivity, arguing these are essential for recouping R&D investments. It strongly opposes measures like international reference pricing and supports the role of pharmacy benefit managers in the drug supply chain. The group advocates for streamlined FDA approval processes and robust enforcement against counterfeit medicines. It frequently submits testimony to committees like the Senate Finance Committee and engages with agencies such as the Department of Health and Human Services and the World Trade Organization.

Criticisms and controversies

The organization has faced sustained criticism from patient groups, lawmakers, and entities like AARP over its lobbying against measures to lower drug prices, such as Medicare negotiation. It has been involved in high-profile legal battles, including challenges to the Inflation Reduction Act. Critics, including Senator Bernie Sanders and organizations like Public Citizen, accuse it of prioritizing profits over patient access, particularly regarding orphan drugs and price hikes for older medicines. Its advertising campaigns and political spending through PACs are often scrutinized for influencing elections and healthcare legislation.

Key initiatives and programs

It runs public campaigns like "GoBoldly" and "From Hope to Cures" to highlight industry innovation in areas like oncology and Alzheimer's disease. The organization sponsors research through partnerships with institutions like the National Institutes of Health and advocates for clinical trial diversity. It operates the "PhRMA Foundation," which provides fellowship funding for young scientists. Other initiatives include supporting patient assistance programs and promoting value-based healthcare agreements between manufacturers and payers like CVS Health and UnitedHealth Group.

Category:Pharmaceutical industry trade groups Category:Organizations based in Washington, D.C. Category:Lobbying organizations in the United States